Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2020 | 1 |
2021 | 3 |
2022 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16.
N Engl J Med. 2021.
PMID: 33200891
Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators.
Das Pradhan A, et al.
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
N Engl J Med. 2022.
PMID: 36342113
Clinical Trial.
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis an …
As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density …
Item in Clipboard
Examining Subtypes of Emerging Adult Situational Drinking: A Replication and Extension Study.
Bernusky HCR, Rapinda KK, Single A, Bilevicius E, Foot M, Ellery M, Keough MT, Johnson EA.
Bernusky HCR, et al.
Subst Use Misuse. 2022;57(1):96-104. doi: 10.1080/10826084.2021.1990337. Epub 2021 Nov 10.
Subst Use Misuse. 2022.
PMID: 34753393
Despite overall heavy use, studies show considerable heterogeneity in emerging adult drinking habits. Lau-Barraco and colleagues (2016 b) identified three subtypes (high, moderate, low) of emerging adult heavy drinkers based on patterns of use across common drinking situat …
Despite overall heavy use, studies show considerable heterogeneity in emerging adult drinking habits. Lau-Barraco and colleagues (2016 b …
Item in Clipboard
Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT).
Bernhardt J, Churilov L, Ellery F, Collier J, Chamberlain J, Langhorne P, Lindley RI, Moodie M, Dewey H, Thrift AG, Donnan G; AVERT Collaboration Group.
Bernhardt J, et al.
Neurology. 2016 Jun 7;86(23):2138-45. doi: 10.1212/WNL.0000000000002459. Epub 2016 Feb 17.
Neurology. 2016.
PMID: 26888985
Free PMC article.
Clinical Trial.
Item in Clipboard
Fatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke.
Bernhardt J, Borschmann K, Collier JM, Thrift AG, Langhorne P, Middleton S, Lindley RI, Dewey HM, Bath P, Said CM, Churilov L, Ellery F, Bladin C, Reid CM, Frayne JH, Srikanth V, Read SJ, Donnan GA; AVERT Trialists Collaboration Group.
Bernhardt J, et al.
Neurology. 2021 Feb 22;96(8):e1156-e1166. doi: 10.1212/WNL.0000000000011106.
Neurology. 2021.
PMID: 33144512
Free PMC article.
Item in Clipboard
Cite
Cite